PL1761492T3 - Szczawian 1-benzylo-4-[(5,6-dimetoksy-1-indanon)-2-ylo]metylopiperydyny (szczawian donepezilu) i jego polimorfy - Google Patents

Szczawian 1-benzylo-4-[(5,6-dimetoksy-1-indanon)-2-ylo]metylopiperydyny (szczawian donepezilu) i jego polimorfy

Info

Publication number
PL1761492T3
PL1761492T3 PL04806734T PL04806734T PL1761492T3 PL 1761492 T3 PL1761492 T3 PL 1761492T3 PL 04806734 T PL04806734 T PL 04806734T PL 04806734 T PL04806734 T PL 04806734T PL 1761492 T3 PL1761492 T3 PL 1761492T3
Authority
PL
Poland
Prior art keywords
oxalate
indanone
dimethoxy
benzyl
polymorphs
Prior art date
Application number
PL04806734T
Other languages
English (en)
Inventor
Venkatasubramanian Radhakrishnan Tarur
Dhananjay Govind Sathe
Avinash Venkataraman Naidu
Umesh Parashram Aher
Original Assignee
Usv Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usv Ltd filed Critical Usv Ltd
Publication of PL1761492T3 publication Critical patent/PL1761492T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4453Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
PL04806734T 2004-06-29 2004-07-22 Szczawian 1-benzylo-4-[(5,6-dimetoksy-1-indanon)-2-ylo]metylopiperydyny (szczawian donepezilu) i jego polimorfy PL1761492T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/879,816 US7439365B2 (en) 2003-11-17 2004-06-29 Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil)
EP04806734A EP1761492B1 (en) 2004-06-29 2004-07-22 1-benzyl-4-¬(5,6-dimethoxy-1-indanone)-2-yl methyl piperidine oxalate (donepezil oxalate) and its polymorphs
PCT/IN2004/000220 WO2006001031A1 (en) 2004-06-29 2004-07-22 1-benzyl-4- ` (5,6-dimethoxy-1-indanone)-2-yl! methyl piperidine oxalate (donepezil oxalate) and its polymorphs

Publications (1)

Publication Number Publication Date
PL1761492T3 true PL1761492T3 (pl) 2010-05-31

Family

ID=34959819

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04806734T PL1761492T3 (pl) 2004-06-29 2004-07-22 Szczawian 1-benzylo-4-[(5,6-dimetoksy-1-indanon)-2-ylo]metylopiperydyny (szczawian donepezilu) i jego polimorfy

Country Status (15)

Country Link
US (1) US7439365B2 (pl)
EP (1) EP1761492B1 (pl)
JP (1) JP2007536209A (pl)
KR (1) KR20060090245A (pl)
CN (1) CN1874998A (pl)
AT (1) ATE448203T1 (pl)
AU (1) AU2004320911A1 (pl)
CA (1) CA2549752C (pl)
DE (1) DE602004024129D1 (pl)
EA (1) EA200700150A1 (pl)
ES (1) ES2336572T3 (pl)
PL (1) PL1761492T3 (pl)
PT (1) PT1761492E (pl)
WO (1) WO2006001031A1 (pl)
ZA (1) ZA200602133B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0401850A3 (en) * 2004-09-15 2008-03-28 Egis Gyogyszergyar Nyilvanosan Donepezil salts for producing pharmaceutical composition
DE102004046497A1 (de) * 2004-09-23 2006-04-06 Helm Ag Donepezil-Salze
US7592459B2 (en) * 2004-09-29 2009-09-22 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
WO2006063025A1 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising donepezil
RU2401125C2 (ru) * 2004-12-27 2010-10-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ стабилизации лекарственного средства против деменции
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
HU227474B1 (en) * 2005-12-20 2011-07-28 Richter Gedeon Nyrt Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
US20100113793A1 (en) * 2006-03-20 2010-05-06 Ind-Swift Laboratories Limited Process for the Preparation of Highly Pure Donepezil
EP2204364B1 (en) 2007-09-28 2013-03-20 Tianjin Hemay Bio-Tech Co., Ltd. Polymorphs of donepezil salts, preparation methods and uses thereof
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
CN102164601A (zh) * 2008-09-30 2011-08-24 帝国制药美国公司 经皮延长给药多奈哌齐组合物及其使用方法
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
US20140243278A1 (en) * 2011-07-05 2014-08-28 Sunil Sadanand Nadkarni Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
CN108976163B (zh) * 2017-06-05 2023-08-11 上海奥博生物医药股份有限公司 一种多奈哌齐双羟萘酸盐新的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DK1048653T3 (da) * 1997-12-05 2004-05-24 Eisai Co Ltd Donepezilpolykrystaller og fremgangsmåde til fremstilling deraf

Also Published As

Publication number Publication date
EP1761492A1 (en) 2007-03-14
AU2004320911A8 (en) 2008-08-21
CA2549752C (en) 2010-04-13
US20050107613A1 (en) 2005-05-19
JP2007536209A (ja) 2007-12-13
CA2549752A1 (en) 2006-01-05
DE602004024129D1 (de) 2009-12-24
EP1761492B1 (en) 2009-11-11
WO2006001031A1 (en) 2006-01-05
EA200700150A1 (ru) 2007-08-31
ES2336572T3 (es) 2010-04-14
US7439365B2 (en) 2008-10-21
ZA200602133B (en) 2007-06-27
ATE448203T1 (de) 2009-11-15
PT1761492E (pt) 2010-02-18
KR20060090245A (ko) 2006-08-10
CN1874998A (zh) 2006-12-06
AU2004320911A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
PL1761492T3 (pl) Szczawian 1-benzylo-4-[(5,6-dimetoksy-1-indanon)-2-ylo]metylopiperydyny (szczawian donepezilu) i jego polimorfy
EA200700673A1 (ru) Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид
IL150509A0 (en) Pharmaceutical compositions containing donepezil hydrocholoride
IL189986A0 (en) Process for producing 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine or hydrochloride thereof
HK1095327A1 (en) 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists
IL166795A (en) N - aryl piperidine substituted biphenylcarboxamides, pharmaceutical composiitons comprising them and method for their preparation
ATE328879T1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
MX2011005090A (es) Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)feni l] piperidina.
IL178766A0 (en) Processes for producing 1 - benzyl - 4 - [(5, 6 - dimethoxy - 1indanon) - 2 - yl] methylpiperidine and hydrochloride thereof
DE60203481D1 (de) Piperidinderivate als neurokinin 1 antagonisten
HK1090051A1 (en) 4-(2-phenylsulfanyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
IL163896A0 (en) Piperidine or 8-aza-bicycloÄ3.2.1Üoct-3-yl derivatives useful as modulators of chemokine receptoractivity (especially ccr5)
EP1935884A3 (en) New crystalline forms of donepezil base
WO2007073888A3 (de) Pharmazeutische zusammensetzung enthaltend donepezilhydrochlorid, tablette hieraus und verfahren zu deren herstellung
WO2009118516A8 (en) Process for the preparation of donepezil hydrochloride
NO20035572L (no) Fremgangsmate til fremstilling av piperidinderivatet fexofenadin
IL188916A0 (en) Process for producing 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-ylidene]methylpiperidine
EP1616861A3 (en) A process for the preparation of keto compounds
SI1531151T1 (sl) Postopek za pripravo 1-benzil-4-(5,6-dimetoksi-1-indanon)2-il)metil- piperidin.hidroklorida (donepezil.hcl)
IL158660A0 (en) Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
WO2005076749A3 (en) A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine
HUP0201673A3 (en) Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-alpha, alpha-dimethylbenzeneacetic acid
EP1841739B8 (en) Process for producing 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl] piperidine or salt thereof via novel intermediate
ATE450527T1 (de) Piperidinderivate als ccr5-inhibitoren
PL375163A1 (pl) Nowe pochodne piperydyny i ich zastosowanie jako inhibitory wychwytu zwrotnego monoaminy